SREBF1 and obesity disorder: Despite the apparent deficit in β‐oxidation, PDAC mice did not exhibit fatty liver, which may be explained by the anti‐lipogenic effect of STAT3 activation, which can prevent steatosis in obesity models by inhibiting sterol regulatory element‐binding protein 1 (SREBP‐1).32